The FDA’s signal that it intends to streamline its review framework for novel tobacco products has sparked sharp criticism from health advocates. While the agency aims to simplify the path to market for compliant companies, critics fear that lowering the evidentiary bar for ingredients and toxicological profiles will erode the protections designed to balance adult smoking cessation with the prevention of youth initiation.

For the 24 million American adults still smoking combustible cigarettes, access to vetted, less-risky alternatives remains a priority. However, Crosby maintains that the focus must remain on the agency's existing mandate: determining whether a product’s public health impact warrants authorization. With thousands of unregulated items already exploiting enforcement gaps, the current priority should be clearing the marketplace of illicit goods rather than expediting new submissions that have not been thoroughly tested for long-term health risks.